New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Study outlines opportunities to achieve Cancer Moonshot goal of reducing cancer death rates

Study outlines opportunities to achieve Cancer Moonshot goal of reducing cancer death rates

by National Institutes of HealthTo achieve the Cancer Moonshot goal, cancer death rates must decline faster. Credit: Shiels M, et al.Cancer Discovery, 2023Researchers from the National Inst
Oncology February 18,2024
Study outlines opportunities to achieve Cancer Moonshot goal of reducing cancer death rates

Study outlines opportunities to achieve Cancer Moonshot goal of reducing cancer death rates

by National Institutes of HealthTo achieve the Cancer Moonshot goal, cancer death rates must decline faster. Credit: Shiels M, et al.Cancer Discovery, 2023Researchers from the National Inst
Oncology February 18,2024
Molecule Linking Cancer Driver and Cell Death Genes May Be Effective Against DLBCL

Molecule Linking Cancer Driver and Cell Death Genes May Be Effective Against DLBCL

November 2023Thomas R. CollinsMolecules that link cancer driver genes and promoters of cell death genes produce potent killing of diffuse large B-cell lymphoma (DLBCL) cells, according to findings pub
Oncology February 18,2024
Molecule Linking Cancer Driver and Cell Death Genes May Be Effective Against DLBCL

Molecule Linking Cancer Driver and Cell Death Genes May Be Effective Against DLBCL

November 2023Thomas R. CollinsMolecules that link cancer driver genes and promoters of cell death genes produce potent killing of diffuse large B-cell lymphoma (DLBCL) cells, according to findings pub
Oncology February 18,2024
IKZF1 Alterations an Independent Marker of AML Risk

IKZF1 Alterations an Independent Marker of AML Risk

February 2024Leah LawrenceMutatedIKZF1was an independent marker of adverse risk in patients with acute myeloid leukemia (AML), and patients whose AML had these alterations were at higher r
Oncology February 18,2024
IKZF1 Alterations an Independent Marker of AML Risk

IKZF1 Alterations an Independent Marker of AML Risk

February 2024Leah LawrenceMutatedIKZF1was an independent marker of adverse risk in patients with acute myeloid leukemia (AML), and patients whose AML had these alterations were at higher r
Oncology February 18,2024
FDA Approves Two Cell-Based SCD Gene Therapies

FDA Approves Two Cell-Based SCD Gene Therapies

February 2024The U.S. Food and Drug Administration (FDA) approved exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel) for the treatment of sickle cell disease (SCD) in patient
Oncology February 18,2024
FDA Approves Two Cell-Based SCD Gene Therapies

FDA Approves Two Cell-Based SCD Gene Therapies

February 2024The U.S. Food and Drug Administration (FDA) approved exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel) for the treatment of sickle cell disease (SCD) in patient
Oncology February 18,2024
Isa-Kd Prolongs PFS to Almost Three Years in Early Relapsed MM Follow-up Study

Isa-Kd Prolongs PFS to Almost Three Years in Early Relapsed MM Follow-up Study

August 2023Katie RobinsonIn patients with early relapsed multiple myeloma (MM), the addition of the anti-CD38 antibody isatuximab (Isa) to carfilzomib-dexamethasone (Kd) maintained the improved progre
Orthopedics & Sports medicine February 18,2024
Isa-Kd Prolongs PFS to Almost Three Years in Early Relapsed MM Follow-up Study

Isa-Kd Prolongs PFS to Almost Three Years in Early Relapsed MM Follow-up Study

August 2023Katie RobinsonIn patients with early relapsed multiple myeloma (MM), the addition of the anti-CD38 antibody isatuximab (Isa) to carfilzomib-dexamethasone (Kd) maintained the improved progre
Orthopedics & Sports medicine February 18,2024
Investigational BCMA-Directed CAR T-Cell Therapy for R/R Multiple Myeloma Provides Deep Responses, Low Toxicity

Investigational BCMA-Directed CAR T-Cell Therapy for R/R Multiple Myeloma Provides Deep Responses, Low Toxicity

October 2023Katie RobinsonA fractionated dose of ARI0002hm, an investigational autologous chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), combined with a boo
Orthopedics & Sports medicine February 18,2024
Investigational BCMA-Directed CAR T-Cell Therapy for R/R Multiple Myeloma Provides Deep Responses, Low Toxicity

Investigational BCMA-Directed CAR T-Cell Therapy for R/R Multiple Myeloma Provides Deep Responses, Low Toxicity

October 2023Katie RobinsonA fractionated dose of ARI0002hm, an investigational autologous chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), combined with a boo
Orthopedics & Sports medicine February 18,2024
Study Proposes Recommendations for Infections During Teclistamab Treatment of R/R MM

Study Proposes Recommendations for Infections During Teclistamab Treatment of R/R MM

February 2024Katie RobinsonWhen using teclistamab to treat patients with relapsed or refractory (R/R) multiple myeloma (MM), clinicians should remain vigilant for a range of infection types and undert
Orthopedics & Sports medicine February 18,2024
Study Proposes Recommendations for Infections During Teclistamab Treatment of R/R MM

Study Proposes Recommendations for Infections During Teclistamab Treatment of R/R MM

February 2024Katie RobinsonWhen using teclistamab to treat patients with relapsed or refractory (R/R) multiple myeloma (MM), clinicians should remain vigilant for a range of infection types and undert
Orthopedics & Sports medicine February 18,2024
The quest to bring osteoarthritis to its knees

The quest to bring osteoarthritis to its knees

by Michael Allen,Horizon: The EU Research & Innovation MagazineCredit: Pixabay/CC0 Public DomainMillions of people in Europe and elsewhere suffer degeneration of joint cartilage in the knee,
Arthritis and Rheumatism February 18,2024
The quest to bring osteoarthritis to its knees

The quest to bring osteoarthritis to its knees

by Michael Allen,Horizon: The EU Research & Innovation MagazineCredit: Pixabay/CC0 Public DomainMillions of people in Europe and elsewhere suffer degeneration of joint cartilage in the knee,
Arthritis and Rheumatism February 18,2024
Arthritic hands: What works (and doesn't) to ease the pain?

Arthritic hands: What works (and doesn't) to ease the pain?

by Denise MannMillions of people who live with the pain and stiffness of arthritis in their hands get steroid or hyaluronic acid injections directly into their finger joints in the hopes of feeling be
Arthritis and Rheumatism February 18,2024
Arthritic hands: What works (and doesn't) to ease the pain?

Arthritic hands: What works (and doesn't) to ease the pain?

by Denise MannMillions of people who live with the pain and stiffness of arthritis in their hands get steroid or hyaluronic acid injections directly into their finger joints in the hopes of feeling be
Arthritis and Rheumatism February 18,2024
Methotrexate reduces pain in hand osteoarthritis with synovitis

Methotrexate reduces pain in hand osteoarthritis with synovitis

by Elana GotkineFor patients with hand osteoarthritis and synovitis, methotrexate has a potentially clinically meaningful effect on reducing pain, with no increase in adverse events, according to a st
Arthritis and Rheumatism February 18,2024
Methotrexate reduces pain in hand osteoarthritis with synovitis

Methotrexate reduces pain in hand osteoarthritis with synovitis

by Elana GotkineFor patients with hand osteoarthritis and synovitis, methotrexate has a potentially clinically meaningful effect on reducing pain, with no increase in adverse events, according to a st
Arthritis and Rheumatism February 18,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com